To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
About This Bill
Floor Vote
Latest Action · March 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.